Buy Mayzent (Siponimod)

What is Mayzent (siponimod)?

 

Mayzent (siponimod) is a sphingosine 1-phosphate receptor modulator and is used for the treatment of adults with multiple sclerosis, and specifically active secondary progressive multiple sclerosis (SPMS). This is the first oral treatment specifically for active SPMS, which encompasses about 80% of relapsing remitting multiple sclerosis (RRMS) cases^[2].

 

How does Mayzent (siponimod) work?

 

Mayzent (siponimod) is a sphingosine 1-phosphate receptor modulator indicated specifically for the treatment of patients with active secondary progressive multiple sclerosis (SPMS).

It works by lowering the number of lymphocytes in peripheral blood with the aim to minimise lymphocyte migration into the central nervous system^[1].

 

Where has Mayzent (siponimod) been approved?

 

Mayzent (siponimod) was approved for multiple sclerosis by:

• Food and Drug Administration (FDA), US, March 26, 2019^[1]

• Therapeutic Goods Administration (TGA), Australia, November 1, 2019^[3]

• European Medical Agency (EMA), European Union, January 13, 2020^[4].

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

 

How is Mayzent (siponimod) taken?

 

Prior to initiating Mayzent (siponimod), assessments are required^[1]. Do NOT take Mayzent (siponimod) if^[1]:

 

• your genotype is CYP2C9 *3*3. Check with your healthcare provider before you start treatment with Mayzent if you are not sure. Your CYP2C9 genotype should be determined by your healthcare provider

• you have had a heart attack, unstable angina (chest pain), certain types of heart failure in the last 6 months, stroke or transient ischemic attack (mini-stroke)

• you have arrhythmia (abnormal heartbeat), certain types of heart block, unless you have a pacemaker.

 

Please refer to the official prescribing information listed in our references section for a full list of precautions before taking Mayzent (siponimod)^[1].

Titration is required for treatment initiation. Please see the official prescribing information listed in our references section for the titration schedule at initiation^[1].

The recommended maintenance dosage is^[1]:

 

• 2 mg taken orally daily.

The recommended maintenance dosage in patients with a CYP2C9 *1/*3 or *2/*3 genotype is^[1]:

 

• 1 mg taken orally daily.

First-dose monitoring is recommended for patients with^[1]:

 

• sinus

• bradycardia

• first- or second-degree [Mobitz type I] atrioventricular (AV) block

• a history of myocardial infarction

• heart failure.

Adjustment in dose may be required based on symptoms and experienced side effects^[1].

Complete information about Mayzent (siponimod) dosage and administration can be found in the official prescribing information listed in our references section^[1].

Note: Please consult with your treating doctor for personalised dosing.

 

Are there any known side effects or adverse reactions of Mayzent (siponimod)?

 

Common adverse reactions

 

The most common adverse reactions listed in the prescribing information include^[1]:

• headache

• hypertension

• increased transaminase

• falls.

 

Serious adverse reactions

 

The serious adverse reactions listed in the prescribing information include^[1]:

 

• increased risk of infections

• macular oedema

• bradyarrhythmia and atrioventricular (AV) conduction delays

• respiratory effects

• liver injury

• increased blood pressure

• foetal risk.

References

1. Summary of Product Characteristics [FDA]: Mayzent (siponimod) [PDF], Novartis, March 2019.

2. Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease. 26 March, 2019.

3. TGA Public Summary: Mayzent (siponimod) [PDF], Novartis, November 2019.

4. Summary of Product Characteristics [EMA]: Mayzent (siponimod) [PDF], Novartis, January 2020.